{"id":"pneumococcal-conjugate-13-valent-vaccine","safety":{"commonSideEffects":[{"rate":"10-20","effect":"Injection site erythema"},{"rate":"5-15","effect":"Injection site swelling"},{"rate":"10-20","effect":"Fever"},{"rate":"5-10","effect":"Irritability"},{"rate":"5-10","effect":"Drowsiness"}]},"_chembl":{"chemblId":"CHEMBL2108573","moleculeType":"Vaccine component"},"_dailymed":{"setId":"e8c6b638-c22f-4c20-ba40-b9d5e85c9541","title":"PREVNAR 13 (PNEUMOCOCCAL 13-VALENT CONJUGATE VACCINE) INJECTION, SUSPENSION [A-S MEDICATION SOLUTIONS]"},"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"The vaccine contains capsular polysaccharides from 13 different serotypes of S. pneumoniae conjugated to diphtheria toxoid, which enhances immunogenicity and T-cell dependent responses. This conjugation allows the vaccine to elicit both humoral and cellular immune responses, providing protection against invasive pneumococcal disease caused by these 13 serotypes. The antibodies produced help opsonize and facilitate clearance of pneumococcal bacteria.","oneSentence":"Pneumococcal conjugate 13-valent vaccine stimulates the immune system to produce antibodies against 13 serotypes of Streptococcus pneumoniae by conjugating polysaccharide antigens to a protein carrier.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T01:29:23.971Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Prevention of invasive pneumococcal disease in infants and children"},{"name":"Prevention of pneumococcal pneumonia and invasive disease in adults"}]},"trialDetails":[{"nctId":"NCT03650114","phase":"PHASE3","title":"Long-term Safety, Tolerability and Effectiveness Study of Ofatumumab in Patients With Relapsing MS","status":"ACTIVE_NOT_RECRUITING","sponsor":"Novartis Pharmaceuticals","startDate":"2018-12-28","conditions":"Relapsing Multiple Sclerosis","enrollment":1882},{"nctId":"NCT07017777","phase":"PHASE3","title":"A Study to Evaluate the Immunogenicity and Safety of 13-valent Pneumococcal Conjugate Vaccine (PCV13i) in Healthy Infants Aged 2 Months (Minimum 6 Weeks)","status":"RECRUITING","sponsor":"CanSino Biologics Inc.","startDate":"2025-11-14","conditions":"Pneumococcal Infections, Streptococcal Infections, Bacterial Infections","enrollment":600},{"nctId":"NCT07019909","phase":"PHASE1","title":"A Study to Learn About How Safe and Effective is 20vPnC and 13vPnC Vaccines in Chinese Adults","status":"COMPLETED","sponsor":"Pfizer","startDate":"2025-07-06","conditions":"Pneumococcal Disease","enrollment":400},{"nctId":"NCT03942328","phase":"PHASE1, PHASE2","title":"Modified Immune Cells (Autologous Dendritic Cells) and a Vaccine (Prevnar) Combined With Immune Checkpoint Inhibition After High-Dose External Beam Radiation Therapy in Treating Patients With Unresectable Liver Cancer","status":"RECRUITING","sponsor":"Mayo Clinic","startDate":"2019-09-19","conditions":"Stage III Hepatocellular Carcinoma AJCC v8, Stage III Intrahepatic Cholangiocarcinoma AJCC v8, Stage IV Hepatocellular Carcinoma AJCC v8","enrollment":85},{"nctId":"NCT05170399","phase":"PHASE4","title":"Vaccine Responses in Patients With B Cell Malignancies","status":"RECRUITING","sponsor":"National Heart, Lung, and Blood Institute (NHLBI)","startDate":"2022-09-14","conditions":"Lymphoma","enrollment":500},{"nctId":"NCT04745559","phase":"PHASE2","title":"Optimizing Cellular and Humoral Immunity by Vaccinating With PCV13 Before and After CAR-T Therapy","status":"ACTIVE_NOT_RECRUITING","sponsor":"H. Lee Moffitt Cancer Center and Research Institute","startDate":"2021-02-18","conditions":"Diffuse Large-Cell Lymphoma, Primary Mediastinal Large B-Cell Lymphoma (PMBCL), Transformed Follicular Lymphoma (TFL)","enrollment":26},{"nctId":"NCT06183216","phase":"PHASE1","title":"A Phase 1b Clinical Trial of 13-valent Pneumococcal Polysaccharide Conjugate Vaccine","status":"COMPLETED","sponsor":"Sinovac Research and Development Co., Ltd.","startDate":"2024-01-04","conditions":"Pneumococcal Infectious Disease","enrollment":140},{"nctId":"NCT06550830","phase":"PHASE1","title":"Clinical Trial of PCV24 in Children Aged 2-17 Years","status":"COMPLETED","sponsor":"Sinovac Life Sciences Co., Ltd.","startDate":"2024-09-07","conditions":"Pneumococcal Infectious Disease","enrollment":119},{"nctId":"NCT06800261","phase":"PHASE1","title":"Clinical Trial of PCV24 in Infants Aged 2-23 Months","status":"RECRUITING","sponsor":"Sinovac Life Sciences Co., Ltd.","startDate":"2025-05-08","conditions":"Pneumococcal Infectious Disease","enrollment":180},{"nctId":"NCT06617715","phase":"PHASE3","title":"Clinical Trial of 13-Valent Pneumococcal Conjugate Vaccine","status":"RECRUITING","sponsor":"Sinovac Life Sciences Co., Ltd.","startDate":"2024-10-23","conditions":"Pneumococcal Infectious Disease","enrollment":3080},{"nctId":"NCT05092386","phase":"PHASE1","title":"Safety and Immunogenicity Study of a 13-valent Pneumococcal Polysaccharide Conjugate Vaccine","status":"COMPLETED","sponsor":"Sinovac Life Sciences Co., Ltd.","startDate":"2023-01-03","conditions":"Pneumococcal Infections","enrollment":310},{"nctId":"NCT07286370","phase":"PHASE2","title":"A Study to Evaluate Safety, Reactogenicity, and Immune Response of GVGH iNTS-TCV Vaccine Against Invasive Nontyphoidal Salmonella Disease and Typhoid Fever in Infants","status":"NOT_YET_RECRUITING","sponsor":"GlaxoSmithKline","startDate":"2026-02-16","conditions":"Salmonella Infections","enrollment":537},{"nctId":"NCT05794230","phase":"PHASE3","title":"Study of a Quadrivalent Meningococcal Conjugate Vaccine (MenACYW Conjugate Vaccine) Given With Routine Pediatric Vaccines in Healthy Infants and Toddlers in India and the Republic of South Africa","status":"COMPLETED","sponsor":"Sanofi Pasteur, a Sanofi Company","startDate":"2023-03-27","conditions":"Meningococcal Immunisation, Healthy Volunteers","enrollment":1528},{"nctId":"NCT06647407","phase":"PHASE1, PHASE2","title":"Safety and Immunogenicity of an Investigational Pentavalent Meningococcal ABCYW Vaccine Against Meningococcal Disease in Children, Toddlers, and Infants","status":"ACTIVE_NOT_RECRUITING","sponsor":"Sanofi Pasteur, a Sanofi Company","startDate":"2024-11-05","conditions":"Meningococcal Immunization, Healthy Volunteers","enrollment":750},{"nctId":"NCT07333352","phase":"PHASE2","title":"PCV24 Clinical Trial in Infants and Young Children Aged 2 Months (Minimum 6 Weeks) to 71 Months","status":"RECRUITING","sponsor":"Shanghai Reinovax Biologics Co.,LTD","startDate":"2025-09-11","conditions":"Pneumococcal Infectious Disease","enrollment":480},{"nctId":"NCT02518555","phase":"PHASE2","title":"Ibrutinib as an Immune Modulating Agent for Patients With Asymptomatic, High-risk CLL/SLL Risk Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma","status":"ACTIVE_NOT_RECRUITING","sponsor":"Jennifer Woyach","startDate":"2016-01-12","conditions":"Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma","enrollment":42},{"nctId":"NCT06675032","phase":"PHASE1","title":"Phase I Clinical Trial of PCV24 in Children Aged 2 Months (Minimum 6 Weeks) to 17 Years","status":"ACTIVE_NOT_RECRUITING","sponsor":"Shanghai Reinovax Biologics Co.,LTD","startDate":"2024-04-27","conditions":"Pneumococcal Infectious Disease","enrollment":230},{"nctId":"NCT05512819","phase":"PHASE3","title":"A Study to Describe the Safety and Immunogenicity of 20vPnC in Infants in India and Taiwan","status":"COMPLETED","sponsor":"Pfizer","startDate":"2022-09-16","conditions":"Pneumococcal Disease","enrollment":541},{"nctId":"NCT06806137","phase":"PHASE3","title":"A Study on the Immune Response and Safety of the Second Dose of an Investigational Chickenpox Vaccine When Given to Healthy Children 3 Months After a First Dose at 12 to 15 Months of Age","status":"RECRUITING","sponsor":"GlaxoSmithKline","startDate":"2025-05-15","conditions":"Chickenpox","enrollment":600},{"nctId":"NCT06855160","phase":"PHASE3","title":"A Study on the Immune Response and Safety of an Investigational Chickenpox Vaccine and a Marketed Measles, Mumps and Rubella Vaccine When Administered as Intramuscular Injection to Healthy Children 12 to 15 Months of Age","status":"RECRUITING","sponsor":"GlaxoSmithKline","startDate":"2025-04-17","conditions":"Chickenpox","enrollment":900},{"nctId":"NCT03069703","phase":"PHASE2","title":"Innovative Anti-pneumococcal Vaccine Strategies in Patients With ANCA-associated Vasculitis Receiving Rituximab Therapy","status":"COMPLETED","sponsor":"Assistance Publique - Hôpitaux de Paris","startDate":"2018-02-05","conditions":"Invasive Pneumococcal Infection","enrollment":96},{"nctId":"NCT05794191","phase":"","title":"A Study To Learn About The Effects Of Pneumococcal Vaccine In People With HIV","status":"COMPLETED","sponsor":"Pfizer","startDate":"2023-03-22","conditions":"HIV, Pneumonia, Infections, Pneumococcal","enrollment":350399},{"nctId":"NCT04429295","phase":"PHASE3","title":"Study of DTwP-HepB-Hib-IPV (SHAN6™) Vaccine Administered Concomitantly With Routine Pediatric Vaccines to Healthy Infants and Toddlers in Thailand","status":"COMPLETED","sponsor":"Sanofi Pasteur, a Sanofi Company","startDate":"2020-06-28","conditions":"Pertussis Immunisation, Diphtheria Immunisation, Polio Immunisation","enrollment":460},{"nctId":"NCT04583618","phase":"PHASE2","title":"Study of a Pneumococcal Conjugate Vaccine in Adults Aged 50 to 84 Years.","status":"COMPLETED","sponsor":"Sanofi","startDate":"2020-10-08","conditions":"Pneumococcal Immunization","enrollment":750},{"nctId":"NCT04398706","phase":"PHASE2","title":"Study of a Pneumococcal Conjugate Vaccine When Administered Concomitantly With Routine Pediatric Vaccines in Healthy Toddlers and Infants","status":"COMPLETED","sponsor":"Sanofi Pasteur, a Sanofi Company","startDate":"2020-05-22","conditions":"Pneumococcal Immunisation, Diphtheria Immunisation, Tetanus Immunisation","enrollment":852},{"nctId":"NCT04460235","phase":"PHASE4","title":"Clinical Trial Assessing the Immunogenicity of an Anti-pneumococcal Vaccination Strategy (PCV13+PPV23 Versus PREVENAR20) in Adult Patients Treated for a Lymphoma","status":"RECRUITING","sponsor":"Poitiers University Hospital","startDate":"2021-09-07","conditions":"Vaccine, Streptococcus Pneumoniae, Lymphoma, Non-Hodgkin","enrollment":160},{"nctId":"NCT04613375","phase":"","title":"PCV13 Effectiveness Study Against Hospitalised VT Pneumococcal CAP in Adults 60 Years and Older","status":"COMPLETED","sponsor":"Pfizer","startDate":"2021-03-12","conditions":"Community Acquired Pneumonia (CAP)","enrollment":1821},{"nctId":"NCT06970756","phase":"PHASE1","title":"A Phase I Clinical Study to Evaluate the Safety of PCV26 in Individuals ≥60","status":"NOT_YET_RECRUITING","sponsor":"Beijing Zhifei Lvzhu Biopharmaceutical Co., Ltd","startDate":"2025-05-27","conditions":"Pneumococcal Diseases","enrollment":60},{"nctId":"NCT03035331","phase":"PHASE1, PHASE2","title":"Dendritic Cell Therapy, Cryosurgery, and Pembrolizumab in Treating Patients With Non-Hodgkin Lymphoma","status":"COMPLETED","sponsor":"Mayo Clinic","startDate":"2017-08-15","conditions":"Aggressive Non-Hodgkin Lymphoma, Indolent Non-Hodgkin Lymphoma, Recurrent Diffuse Large B-Cell Lymphoma","enrollment":11},{"nctId":"NCT06279624","phase":"","title":"Effectiveness of the PCV13 in Older Thai Adults","status":"COMPLETED","sponsor":"Mahidol University","startDate":"2024-02-05","conditions":"Community-acquired Pneumonia","enrollment":825},{"nctId":"NCT01527591","phase":"NA","title":"Pneumococcal Conjugate Vaccine 13 (Prevnar13®) in Children Who Are Solid Organ Transplant Recipients (SOT)","status":"ACTIVE_NOT_RECRUITING","sponsor":"University of California, Los Angeles","startDate":"2012-02-01","conditions":"Infection in Solid Organ Transplant Recipients","enrollment":17},{"nctId":"NCT06608199","phase":"PHASE3","title":"A Phase 3 Study to Evaluate the Immunogenicity and Safety of Minhai's PCV13-DT/TT Vaccine As Compared to Pfizer's PCV13 Vaccine","status":"RECRUITING","sponsor":"Beijing Minhai Biotechnology Co., Ltd","startDate":"2024-11-01","conditions":"Pneumococcal Vaccines, Pneumococcal Infections","enrollment":500},{"nctId":"NCT06740630","phase":"PHASE3","title":"A Study on the Immune Response and Safety of an Investigational Chickenpox Vaccine When Given to Healthy Children 12 to 15 Months of Age","status":"RECRUITING","sponsor":"GlaxoSmithKline","startDate":"2025-01-10","conditions":"Chickenpox","enrollment":1840},{"nctId":"NCT03547271","phase":"PHASE3","title":"Immunogenicity and Safety Study of a Quadrivalent Meningococcal Conjugate Vaccine When Co-administered With Routine Pediatric Vaccines in Healthy Infants and Toddlers in Europe","status":"COMPLETED","sponsor":"Sanofi Pasteur, a Sanofi Company","startDate":"2018-12-14","conditions":"Meningococcal Infections","enrollment":1660},{"nctId":"NCT04080531","phase":"PHASE4","title":"Influenza Vaccination for Flu Prevention in Patients With Plasma Cell Disorders","status":"COMPLETED","sponsor":"Emory University","startDate":"2019-10-18","conditions":"Plasma Cell Neoplasm","enrollment":165},{"nctId":"NCT05084508","phase":"PHASE2","title":"A Study on the Immune Response and Safety of Various Potencies of an Investigational Chickenpox Vaccine Compared With a Marketed Chickenpox Vaccine, Given to Healthy Children 12 to 15 Months of Age","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2022-02-03","conditions":"Chickenpox","enrollment":800},{"nctId":"NCT06703203","phase":"PHASE1, PHASE2","title":"Phase I/II Clinical Trial of 26-valent Pneumococcal Conjugate Vaccine","status":"ENROLLING_BY_INVITATION","sponsor":"Beijing Zhifei Lvzhu Biopharmaceutical Co., Ltd","startDate":"2024-08-27","conditions":"Pneumococcal Vaccines","enrollment":450},{"nctId":"NCT06693895","phase":"PHASE3","title":"A Study on the Safety of an Investigational Chickenpox Vaccine, When Given to Healthy Children, 12 to 15 Months of Age","status":"RECRUITING","sponsor":"GlaxoSmithKline","startDate":"2024-11-26","conditions":"Chickenpox","enrollment":750},{"nctId":"NCT03848065","phase":"PHASE1","title":"Safety, Tolerability, and Immunogenicity of V114 in Healthy Japanese Infants (V114-028)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2019-04-02","conditions":"Pneumococcal Infections","enrollment":133},{"nctId":"NCT01926860","phase":"PHASE4","title":"PCV13 + Hepatitis a Vaccine for Adults","status":"COMPLETED","sponsor":"Helsinki University Central Hospital","startDate":"2013-08-24","conditions":"Measurement of Immune Response to Prevenar13, Measurement of Immune Response to Hepatitis a","enrollment":305},{"nctId":"NCT06698198","phase":"PHASE1","title":"Safety and Immunogenicity of a Pneumococcal Conjugate Vaccine Candidate in Healthy Adults (19-49 Years)","status":"COMPLETED","sponsor":"Sanofi Pasteur, a Sanofi Company","startDate":"2018-12-03","conditions":"Pneumococcal Immunization","enrollment":175},{"nctId":"NCT03165981","phase":"PHASE4","title":"Fever After Simultaneous Versus Sequential Vaccination in Young Children","status":"COMPLETED","sponsor":"Duke University","startDate":"2017-08-25","conditions":"Fever After Vaccination, Fever, Febrile Seizure","enrollment":221},{"nctId":"NCT03489018","phase":"PHASE4","title":"The Effect of Fractional Doses of Pneumococcal Conjugate Vaccines on Immunogenicity and Carriage in Kenyan Infants","status":"COMPLETED","sponsor":"London School of Hygiene and Tropical Medicine","startDate":"2019-03-21","conditions":"Pneumococcal Infection, Streptococcus Pneumoniae Infection, Invasive Pneumococcal Disease, Protection Against","enrollment":2100},{"nctId":"NCT03574389","phase":"PHASE3","title":"A Study Assessing 13-valent Pneumococcal Conjugate Vaccine in Healthy Chinese Infants and Young Children","status":"COMPLETED","sponsor":"Pfizer","startDate":"2018-06-23","conditions":"Pneumococcal Infections, Pneumococcal Conjugate Vaccine","enrollment":936},{"nctId":"NCT03537508","phase":"PHASE3","title":"Immunogenicity and Safety of a Quadrivalent Meningococcal Conjugate Vaccine When Administered Concomitantly With Routine Pediatric Vaccines in Healthy Infants and Toddlers in the US","status":"COMPLETED","sponsor":"Sanofi Pasteur, a Sanofi Company","startDate":"2018-04-25","conditions":"Healthy Volunteers (Meningococcal Infection)","enrollment":2627},{"nctId":"NCT05759520","phase":"PHASE3","title":"Phase III Clinical Trial of 13-valent Pneumococcal Conjugate Vaccine (Multivalent Conjugate) in Infants","status":"ACTIVE_NOT_RECRUITING","sponsor":"Fosun Adgenvax Biopharmaceutical Co.,Ltd.","startDate":"2022-11-04","conditions":"Streptococcus Pneumoniae Infection","enrollment":1800},{"nctId":"NCT04633226","phase":"PHASE3","title":"Safety and Immunogenicity of V114 in Healthy Infants in South Korea (V114-036)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2021-02-10","conditions":"Pneumococcal Disease","enrollment":58},{"nctId":"NCT05408429","phase":"PHASE3","title":"Safety and Immunogenicity of 20vPnC in Toddlers With 2 Prior Doses of Prevenar 13","status":"COMPLETED","sponsor":"Pfizer","startDate":"2022-06-24","conditions":"Pneumococcal Disease","enrollment":356},{"nctId":"NCT05667740","phase":"PHASE1","title":"Safety, Tolerability and Immunogenicity of an Inactivated Whole-cell Pneumococcal Vaccine Gamma-PN3.","status":"COMPLETED","sponsor":"GPN Vaccines","startDate":"2023-01-16","conditions":"Pneumococcal Infections","enrollment":118},{"nctId":"NCT04535037","phase":"PHASE4","title":"A Study to Evaluate Immunogenicity and Safety of GlaxoSmithKline (GSK)'s Infanrix Hexa Vaccine (DTPa-HBV-IPV/Hib) Versus MCM Vaccine BV's Vaxelis Vaccine (DTaP5-HBV-IPV-Hib) in Healthy Infants and Toddlers","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2021-05-26","conditions":"Diphtheria","enrollment":500},{"nctId":"NCT04275284","phase":"","title":"Persistence of Immunogenicity Following Reduced PCV Dosing Schedules in South African Children","status":"COMPLETED","sponsor":"University of Witwatersrand, South Africa","startDate":"2020-02-14","conditions":"Pneumonia, Meningitis","enrollment":600},{"nctId":"NCT05934890","phase":"PHASE3","title":"A Phase 3 Study to Evaluate the Immunogenicity and Safety of Walvax's PCV13-TT as Compared to Pfizer's PCV13","status":"ACTIVE_NOT_RECRUITING","sponsor":"Walvax Biotechnology Co., Ltd.","startDate":"2023-11-23","conditions":"Pneumococcal Disease, Invasive","enrollment":630},{"nctId":"NCT03691610","phase":"PHASE3","title":"Immunogenicity and Safety Study of a Quadrivalent Meningococcal Conjugate Vaccine Administered Concomitantly With Routine Pediatric Vaccines in Healthy Infants and Toddlers","status":"COMPLETED","sponsor":"Sanofi Pasteur, a Sanofi Company","startDate":"2018-10-04","conditions":"Healthy Volunteers (Meningococcal Infection)","enrollment":950},{"nctId":"NCT06450379","phase":"","title":"Impact of Vaccines on Antimicrobial Microbial Resistance","status":"COMPLETED","sponsor":"Malawi Liverpool Wellcome Programme","startDate":"2021-03-15","conditions":"Vaccine","enrollment":13200},{"nctId":"NCT05329259","phase":"PHASE4","title":"A Study to Describe the Safety of a Vaccine (Called 13vPnC) in Healthy People 18 to 49 Years of Age in India","status":"COMPLETED","sponsor":"Pfizer","startDate":"2022-10-06","conditions":"Pneumococcal Disease","enrollment":200},{"nctId":"NCT05489328","phase":"PHASE1","title":"Safety and Immunogenicity of Pneumococcal Conjugate Formulations in Healthy Adults 18 Through 49 Years of Age","status":"COMPLETED","sponsor":"Pfizer","startDate":"2022-08-15","conditions":"Pneumococcal Disease","enrollment":394},{"nctId":"NCT04841369","phase":"PHASE3","title":"Phase III Clinical Trial of a Candidate PCV13 in Healthy People Aged 6 Weeks and Above (PICTPCV13i)","status":"COMPLETED","sponsor":"CanSino Biologics Inc.","startDate":"2021-04-13","conditions":"Pneumococcal Infections, Streptococcal Infections, Bacterial Infections","enrollment":3420},{"nctId":"NCT03384589","phase":"PHASE2, PHASE3","title":"CIRN Pneumococcal Conjugate Vaccine 1 vs. 2 Dose Priming Study","status":"COMPLETED","sponsor":"University of British Columbia","startDate":"2018-08-23","conditions":"Invasive Pneumococcal Disease, Protection Against, Streptococcus Pneumoniae Infection","enrollment":248},{"nctId":"NCT03530124","phase":"PHASE4","title":"Apnea in Hospitalized Preterm Infants Following the Administration of Routine Childhood Vaccines","status":"COMPLETED","sponsor":"Duke University","startDate":"2018-07-17","conditions":"Apnea, Apnea Neonatal, Prematurity","enrollment":223},{"nctId":"NCT04546425","phase":"PHASE3","title":"20-valent Pneumococcal Conjugate Vaccine Safety and Immunogenicity Study of a 3-Dose Series in Healthy Infants","status":"COMPLETED","sponsor":"Pfizer","startDate":"2020-09-09","conditions":"Pneumococcal Disease","enrollment":1258},{"nctId":"NCT03673462","phase":"PHASE3","title":"Safety of a Quadrivalent Meningococcal Conjugate Vaccine Administered Concomitantly With Routine Pediatric Vaccines in Healthy Infants and Toddlers","status":"COMPLETED","sponsor":"Sanofi Pasteur, a Sanofi Company","startDate":"2018-09-17","conditions":"Healthy Volunteers (Meningococcal Infection)","enrollment":2797},{"nctId":"NCT04382326","phase":"PHASE3","title":"20-valent Pneumococcal Conjugate Vaccine Safety and Immunogenicity Study of a 4-Dose Series in Healthy Infants","status":"COMPLETED","sponsor":"Pfizer","startDate":"2020-05-20","conditions":"Pneumococcal Disease","enrollment":1997},{"nctId":"NCT02637583","phase":"PHASE4","title":"Sequential Versus Simultaneous Pneumococcal Vaccination in Elderly: Immunological Memory and Antibody Levels","status":"COMPLETED","sponsor":"Jena University Hospital","startDate":"2017-10-18","conditions":"Pneumococcal Infections","enrollment":123},{"nctId":"NCT03565159","phase":"PHASE4","title":"Pneumococcal Vaccination to Accelerate Immune Recovery in Sepsis Survivors","status":"COMPLETED","sponsor":"Guy's and St Thomas' NHS Foundation Trust","startDate":"2018-08-02","conditions":"Sepsis","enrollment":214},{"nctId":"NCT03632720","phase":"PHASE3","title":"Immunogenicity and Safety of a Quadrivalent Meningococcal Conjugate Vaccine in Infants and Toddlers When Administered Concomitantly With Routine Pediatric Vaccines in the United Kingdom","status":"COMPLETED","sponsor":"Sanofi Pasteur, a Sanofi Company","startDate":"2018-10-10","conditions":"Healthy Volunteers (Meningococcal Infection)","enrollment":788},{"nctId":"NCT03630705","phase":"PHASE3","title":"Safety and Immunogenicity of a Quadrivalent Meningococcal Conjugate Vaccine When Administered Concomitantly With Routine Pediatric Vaccines in Healthy Infants and Toddlers in the Russian Federation and Mexico","status":"COMPLETED","sponsor":"Sanofi Pasteur, a Sanofi Company","startDate":"2018-10-17","conditions":"Healthy Volunteers (Meningococcal Infection)","enrollment":525},{"nctId":"NCT03565900","phase":"PHASE3","title":"A Study to Evaluate the Safety, Tolerability, and Immunogenicity of V114 in Allogeneic Hematopoietic Stem Cell Transplant Recipients (V114-022/PNEU-STEM)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2018-09-12","conditions":"Pneumococcal Infections","enrollment":277},{"nctId":"NCT03893448","phase":"PHASE3","title":"Safety, Tolerability, and Immunogenicity of V114 in Healthy Infants (V114-029)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2019-06-19","conditions":"Pneumococcal Infections, Pneumococcal Vaccines","enrollment":1720},{"nctId":"NCT03692871","phase":"PHASE3","title":"A Study to Evaluate the Safety and Tolerability of V114 and Prevnar 13™ in Healthy Infants (V114-031/PNEU-LINK)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2018-12-14","conditions":"Pneumococcal Infections","enrollment":2409},{"nctId":"NCT04384107","phase":"PHASE3","title":"Study to Evaluate the Safety, Tolerability, and Immunogenicity of V114 in Healthy Japanese Infants (V114-033)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2020-07-01","conditions":"Pneumococcal Infections","enrollment":694},{"nctId":"NCT04031846","phase":"PHASE3","title":"Safety, Tolerability, and Immunogenicity of V114 in Healthy Infants (V114-025)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2019-09-04","conditions":"Pneumococcal Infections","enrollment":1184},{"nctId":"NCT05939219","phase":"NA","title":"Consistency, Immunogenicity, and Safety of Three Batches of 15-valent Pneumococcal Conjugate Vaccine","status":"UNKNOWN","sponsor":"Beijing Zhifei Lvzhu Biopharmaceutical Co., Ltd","startDate":"2023-07-01","conditions":"Healthy Volunteers","enrollment":2346},{"nctId":"NCT04379713","phase":"PHASE3","title":"20-valent Pneumococcal Conjugate Vaccine Safety Study in Healthy Infants","status":"COMPLETED","sponsor":"Pfizer","startDate":"2020-05-21","conditions":"Pneumococcal Disease","enrollment":1511},{"nctId":"NCT03921424","phase":"PHASE3","title":"Safety and Immunogenicity of V114 in Children Infected With Human Immunodeficiency Virus (HIV) (V114-030/PNEU-WAY PED)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2019-11-05","conditions":"Pneumococcal Infections","enrollment":407},{"nctId":"NCT01272999","phase":"","title":"Impact of Prevnar 13 on Ear Infections in Children","status":"COMPLETED","sponsor":"Pfizer","startDate":"2010-05-21","conditions":"Acute Otitis Media, Mastoiditis","enrollment":391},{"nctId":"NCT04016714","phase":"PHASE3","title":"Safety, Tolerability, and Immunogenicity of a 3-dose Regimen of V114 in Healthy Infants (PNEU-PED-EU-2/V114-026)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2019-08-28","conditions":"Pneumococcal Infections","enrollment":1191},{"nctId":"NCT04530838","phase":"PHASE3","title":"20-valent Pneumococcal Conjugate Vaccine Safety and Immunogenicity Study in Healthy Japanese Infants","status":"COMPLETED","sponsor":"Pfizer","startDate":"2020-09-16","conditions":"Pneumococcal Disease","enrollment":668},{"nctId":"NCT05316831","phase":"PHASE4","title":"Immune Response After Pneumococcal Vaccination in Patient With Chronic Lymphocytic Leukemia","status":"COMPLETED","sponsor":"Region Örebro County","startDate":"2019-01-01","conditions":"CLL, Vaccine Response","enrollment":77},{"nctId":"NCT03762824","phase":"PHASE4","title":"Combined Pneumococcal Conjugate and Polysaccharide Vaccination in Inflammatory Rheumatic Disease","status":"COMPLETED","sponsor":"Region Skane","startDate":"2016-06-14","conditions":"Rheumatoid Arthritis, Systemic Lupus, Sjögren Syndrome","enrollment":300},{"nctId":"NCT05721456","phase":"PHASE3","title":"Evaluation of the Non-Inferiority of a 12-Valent Pneumococcal Conjugate Vaccine in Healthy Children in Brazil.","status":"UNKNOWN","sponsor":"Maria de Lourdes de Sousa Maia, MD","startDate":"2023-08-28","conditions":"Pneumococcal Vaccines","enrollment":2400},{"nctId":"NCT03620162","phase":"PHASE3","title":"A Study to Evaluate the Interchangeability of V114 and Prevnar 13™ in Healthy Infants (V114-027/PNEU-DIRECTION)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2018-10-18","conditions":"Pneumococcal Infections","enrollment":900},{"nctId":"NCT03885934","phase":"PHASE3","title":"Safety and Immunogenicity of Catch-up Vaccination Regimens of V114 (V114-024)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2019-06-25","conditions":"Pneumococcal Infections","enrollment":606},{"nctId":"NCT05602480","phase":"PHASE1","title":"Phase I Clinical Trial of a Candidate PCV13 in Healthy People","status":"UNKNOWN","sponsor":"Wuhan BravoVax Co., Ltd.","startDate":"2022-11-01","conditions":"Pneumococcal Infections","enrollment":264},{"nctId":"NCT02851056","phase":"EARLY_PHASE1","title":"Survivin Vaccine : Multiple Myeloma Autologous Hematopoietic Cell Transplant (HCT)","status":"COMPLETED","sponsor":"H. Lee Moffitt Cancer Center and Research Institute","startDate":"2016-09-27","conditions":"Multiple Myeloma","enrollment":14},{"nctId":"NCT04100772","phase":"PHASE1","title":"Phase I Clinical Trial of a Candidate PCV13 in Healthy People Aged 6 Weeks and Above","status":"COMPLETED","sponsor":"CanSino Biologics Inc.","startDate":"2020-05-18","conditions":"Pneumococcal Infections, Streptococcal Infections, Bacterial Infections","enrollment":237},{"nctId":"NCT03873727","phase":"PHASE2","title":"Revaccination With PPS23 Boosted or Not by PCV13 in Splenectomised Patients.","status":"UNKNOWN","sponsor":"Assistance Publique - Hôpitaux de Paris","startDate":"2019-08-27","conditions":"Splenectomised Patients","enrollment":39},{"nctId":"NCT00688870","phase":"PHASE3","title":"Study Evaluating A 13-Valent Pneumococcal Conjugate Vaccine Administered to Infants in Taiwan","status":"COMPLETED","sponsor":"Wyeth is now a wholly owned subsidiary of Pfizer","startDate":"2008-06-05","conditions":"Vaccines, Pneumococcal Conjugate Vaccine","enrollment":168},{"nctId":"NCT01953510","phase":"PHASE2, PHASE3","title":"Trial of Pneumococcal Vaccine Schedules in Ho Chi Minh City, Vietnam","status":"COMPLETED","sponsor":"Murdoch Childrens Research Institute","startDate":"2013-09-30","conditions":"Pneumococcal Vaccines","enrollment":1400},{"nctId":"NCT02274415","phase":"PHASE2","title":"Immunogenicity Study of an Anti-pneumococcal Vaccination Strategy in Patients With Sickle Cells Disease","status":"COMPLETED","sponsor":"Assistance Publique - Hôpitaux de Paris","startDate":"2013-09-16","conditions":"Invasive Pneumococcal Infections, Sickle Cells Disease","enrollment":116},{"nctId":"NCT02049138","phase":"PHASE2","title":"An Open-label Extension Study Evaluating the Safety and Efficacy of Upadacitinib (ABT-494) in Adults With Rheumatoid Arthritis","status":"COMPLETED","sponsor":"AbbVie","startDate":"2014-01-24","conditions":"Rheumatoid Arthritis","enrollment":493},{"nctId":"NCT02447718","phase":"PHASE4","title":"Vaccinating Children After Chemotherapy","status":"COMPLETED","sponsor":"Canadian Immunization Research Network","startDate":"2015-11-16","conditions":"Acute Lymphoblastic Leukemia","enrollment":156},{"nctId":"NCT03480802","phase":"PHASE3","title":"A Study to Evaluate the Safety, Tolerability, and Immunogenicity of V114 Followed by PNEUMOVAX™23 in Adults Infected With Human Immunodeficiency Virus (HIV) (V114-018)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2018-07-06","conditions":"Pneumococcal Infections","enrollment":302},{"nctId":"NCT03896477","phase":"PHASE3","title":"Study of 10-valent Pneumococcal Conjugate Vaccine (Pneumosil) Administered in a 2+1 Schedule to Healthy Infants","status":"COMPLETED","sponsor":"PATH","startDate":"2019-07-18","conditions":"Pneumonia, Pneumococcal","enrollment":660},{"nctId":"NCT03205371","phase":"PHASE3","title":"Immunogenicity and Safety of a Meningococcal Conjugate Vaccine Given Concomitantly With Other Vaccines in Toddlers","status":"COMPLETED","sponsor":"Sanofi Pasteur, a Sanofi Company","startDate":"2016-11-07","conditions":"Meningitis, Meningococcal","enrollment":1183},{"nctId":"NCT01049035","phase":"PHASE2","title":"A Study of a Quadrivalent Meningococcal Tetanus Protein Conjugate Vaccine in Infants and Toddlers","status":"COMPLETED","sponsor":"Sanofi Pasteur, a Sanofi Company","startDate":"2009-12-16","conditions":"Meningitis, Meningococcal Infection","enrollment":580},{"nctId":"NCT02547493","phase":"NA","title":"Vaccination Against Pneumococcal in Naïve Abatacept Rheumatoid Arthritis Patients","status":"COMPLETED","sponsor":"University Hospital, Montpellier","startDate":"2016-03-03","conditions":"Rheumatoid Arthritis","enrollment":80},{"nctId":"NCT03550313","phase":"PHASE2","title":"Study to Evaluate the Safety and Immunogenicity of a Multivalent Pneumococcal Vaccine Given With Prevnar 13 in Healthy Infants","status":"TERMINATED","sponsor":"Pfizer","startDate":"2018-06-01","conditions":"Pneumococcal Infections","enrollment":565},{"nctId":"NCT00427895","phase":"PHASE3","title":"Study Comparing a 13-valent Pneumococcal Conjugate Vaccine With 23-valent Pneumococcal Polysaccharide Vaccine in Adults","status":"COMPLETED","sponsor":"Pfizer","startDate":"2007-02-27","conditions":"Pneumococcal Infections","enrollment":2141},{"nctId":"NCT00853749","phase":"PHASE3","title":"Immune Response In Children Revaccinated With Pneumococcal Conjugate Vaccine","status":"COMPLETED","sponsor":"Wyeth is now a wholly owned subsidiary of Pfizer","startDate":"2009-05-05","conditions":"Invasive Pneumococcal Disease","enrollment":89},{"nctId":"NCT03480763","phase":"PHASE3","title":"A Study to Evaluate the Safety, Tolerability, and Immunogenicity of V114 Followed by PNEUMOVAX™23 in Healthy Adults 50 Years of Age or Older (V114-016/PNEU-PATH)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2018-06-22","conditions":"Pneumococcal Infections","enrollment":652}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":4,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["Prevenar13"],"phase":"marketed","status":"active","brandName":"pneumococcal conjugate 13 valent vaccine","genericName":"pneumococcal conjugate 13 valent vaccine","companyName":"University of Siena","companyId":"university-of-siena","modality":"Biologic","firstApprovalDate":"","aiSummary":"Pneumococcal conjugate 13-valent vaccine stimulates the immune system to produce antibodies against 13 serotypes of Streptococcus pneumoniae by conjugating polysaccharide antigens to a protein carrier. Used for Prevention of invasive pneumococcal disease in infants and children, Prevention of pneumococcal pneumonia and invasive disease in adults.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}